Filing Details

Accession Number:
0001225208-20-000299
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-03 16:20:53
Reporting Period:
2020-01-01
Accepted Time:
2020-01-03 16:20:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
885725 Boston Scientific Corp BSX Surgical & Medical Instruments & Apparatus (3841) 042695240
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1529708 Maulik Nanavaty 300 Boston Scientific Way
Marlborough MA 01752-1234
Svp & Pres, Neuromodulation No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-01-01 7,950 $0.00 263,144 No 4 M Direct
Common Stock Disposition 2020-01-01 2,925 $45.22 260,219 No 4 F Direct
Common Stock Acquisiton 2020-01-02 6,616 $16.31 266,835 No 4 M Direct
Common Stock Acquisiton 2020-01-02 3,007 $13.08 269,842 No 4 M Direct
Common Stock Disposition 2020-01-02 9,623 $45.33 260,219 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Performance Share Units Disposition 2020-01-01 7,950 $0.00 7,950 $0.00
Common Stock Stock Option (Right to Buy) Disposition 2020-01-02 6,616 $0.00 6,616 $16.31
Common Stock Stock Option (Right to Buy) Disposition 2020-01-02 3,007 $0.00 3,007 $13.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-12-31 2019-12-31 No 4 M Direct
19,246 2025-02-23 No 4 M Direct
0 2024-02-24 No 4 M Direct
Footnotes
  1. On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019.
  2. Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
  3. This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.
  4. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $45.21 to $45.55, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
  6. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.
  7. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.